1. Day 1 ·
    Widely discussedHot take

    European biotech leaders sound alarm on regional decline

    Nine pharma leaders are publicly pushing for faster clinical trials, stronger IP protections, and fiscal flexibility after new reporting on Europe's biotech sector losing ground to the US and China, sparking discussion about whether policy fixes can reverse the slide.

    The dominant readingIndustry leaders frame Europe's slump as a policy failure that speedier trials and IP reform could still reverse.

    moderate volume↑ growingThat day's page →

  2. Day 2 ·
    • Was a hot take, now a debate
    Widely discussedDebate

    European biotech leaders sound alarm on regional decline

    New that dayNo new developments beyond the original reporting have surfaced in today's sources.

    Nine pharma leaders are publicly pushing for faster clinical trials, stronger intellectual-property protections, and fiscal flexibility after reporting that Europe's biotech sector is losing ground to the US and China, sparking argument over whether policy fixes can reverse the slide.

    The dominant readingIndustry executives frame Europe's regulatory sluggishness and fragmented IP protections as the core reasons capital and talent are migrating to the US and China.

    The pushbackSome commentators counter that the letter reflects industry self-interest in loosening pricing and IP rules rather than a neutral diagnosis of Europe's competitiveness problem.

    Anxiousmoderate volume↑ growingThat day's page →

Also running in Health

Every running conversation →The latest day →